Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-derived cell models as preclinical tools for genome-directed targeted therapy.
Lee JY, Kim SY, Park C, Kim NK, Jang J, Park K, Yi JH, Hong M, Ahn T, Rath O, Schueler J, Kim ST, Do IG, Lee S, Park SH, Ji YI, Kim D, Park JO, Park YS, Kang WK, Kim KM, Park WY, Lim HY, Lee J. Lee JY, et al. Among authors: park c, park ys, park sh, park jo, park k, park wy. Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627. Oncotarget. 2015. PMID: 26296973 Free PMC article.
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis.
Kim ST, Lee J, Hong M, Park K, Park JO, Ahn T, Park SH, Park YS, Lim HY, Sun JM, Ahn JS, Ahn MJ, Kim HC, Sohn TS, Choi DI, Cho JH, Heo JS, Kwon W, Uhm SW, Lee H, Min BH, Hong SN, Kim DH, Jung SH, Park W, Kim KM, Kang WK, Park K. Kim ST, et al. Among authors: park ys, park w, park jo, park sh, park k. Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. Oncotarget. 2015. PMID: 26396172 Free PMC article. Clinical Trial.
The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors.
Lim SH, Kim SY, Kim K, Jang H, Ahn S, Kim KM, Kim NK, Park W, Lee SJ, Kim ST, Park SH, Park JO, Park YS, Lee SH, Lim HY, Park K, Kang WK, Lee J. Lim SH, et al. Among authors: park ys, park w, park sh, park jo, park k. Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. Oncotarget. 2017. PMID: 27906677 Free PMC article.
Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma.
Jang J, Rath O, Schueler J, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY, Kwon GY, Park WY, Lee J, Park SH. Jang J, et al. Among authors: park sh, park wy. Transl Oncol. 2017 Jun;10(3):304-310. doi: 10.1016/j.tranon.2017.01.016. Epub 2017 Mar 16. Transl Oncol. 2017. PMID: 28325666 Free PMC article.
Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences.
Cho M, Ahn S, Hong M, Bang H, Van Vrancken M, Kim S, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Sun JM, Lee SH, Ahn MJ, Park K, Kim DH, Lee S, Park W, Kim KM. Cho M, et al. Among authors: park ys, park w, park sh, park jo, park k. Oncotarget. 2017 Jun 27;8(26):42478-42486. doi: 10.18632/oncotarget.17199. Oncotarget. 2017. PMID: 28477007 Free PMC article.
Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials.
Kim ST, Kim KM, Kim NKD, Park JO, Ahn S, Yun JW, Kim KT, Park SH, Park PJ, Kim HC, Sohn TS, Choi DI, Cho JH, Heo JS, Kwon W, Lee H, Min BH, Hong SN, Park YS, Lim HY, Kang WK, Park WY, Lee J. Kim ST, et al. Among authors: park pj, park ys, park jo, park sh, park wy. Oncologist. 2017 Oct;22(10):1169-1177. doi: 10.1634/theoncologist.2017-0020. Epub 2017 Jul 12. Oncologist. 2017. PMID: 28701572 Free PMC article.
11,240 results
You have reached the last available page of results. Please see the User Guide for more information.